{"id":"levofloxacin-metronidazole","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-15","effect":"Metallic taste (metronidazole)"},{"rate":"3-5","effect":"Headache"},{"rate":"1-2","effect":"Tendinopathy (fluoroquinolone-related)"},{"rate":"1-2","effect":"QT prolongation"},{"rate":"1-3","effect":"Photosensitivity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in gram-negative and gram-positive bacteria. Metronidazole is a nitroimidazole antibiotic that is reduced to reactive intermediates inside anaerobic bacteria, causing DNA strand breaks and cell death. Together, they provide synergistic coverage against both aerobic and anaerobic pathogens, commonly used in mixed infections.","oneSentence":"This combination uses levofloxacin (a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV) and metronidazole (a nitroimidazole that damages bacterial DNA) to provide broad-spectrum anaerobic and aerobic bacterial coverage.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:52:07.146Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mixed aerobic and anaerobic bacterial infections"},{"name":"Intra-abdominal infections"},{"name":"Pelvic inflammatory disease"},{"name":"Diabetic foot infections with mixed flora"}]},"trialDetails":[{"nctId":"NCT07487142","phase":"PHASE3","title":"Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding\"","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-06-10","conditions":"H Pylori Infection","enrollment":121},{"nctId":"NCT07455448","phase":"","title":"Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-03","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":7228},{"nctId":"NCT07405684","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp First-line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":544},{"nctId":"NCT07405697","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp Rescue Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":"Helicobacter Pylori Infection","enrollment":290},{"nctId":"NCT05332444","phase":"PHASE4","title":"Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2022-04-11","conditions":"Helicobacter Pylori Infection","enrollment":450},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT07021729","phase":"PHASE4","title":"Comparison of Two Treatment Regimens of Helicobacter Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Rehman Medical Institute - RMI","startDate":"2025-12","conditions":"Helicobacter Pylori Infection","enrollment":156},{"nctId":"NCT05946655","phase":"NA","title":"Diagnostics of Chronic Endometritis in Infertility","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2021-04-01","conditions":"Infertility Unexplained, Abnormal Uterine Bleeding, Intrauterine Disorder","enrollment":102},{"nctId":"NCT06760065","phase":"PHASE3","title":"Comparison of Keverprazan Hydrochloride-Amoxicillin Dual Therapy and Susceptibility-Guided Quadruple Therapy for Helicobacter Pylori Rescue Treatment","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2025-01-15","conditions":"Helicobacter Pylori Infection Helicobacter Pylori Eradication Patient Education","enrollment":316},{"nctId":"NCT06650540","phase":"NA","title":"Levofloxacin Plus Metronidazole Suppositories Versus Levofloxacin Co-administered with Metronidazole Tablets in Chronic Endometritis","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2024-10-22","conditions":"IVF","enrollment":800},{"nctId":"NCT06275204","phase":"","title":"H. Pylori Screen-and-treat Study in a Population of Young Adults","status":"RECRUITING","sponsor":"University of Latvia","startDate":"2024-03-04","conditions":"Gastric Cancer, H Pylori Infection, H Pylori Eradication","enrollment":6800},{"nctId":"NCT06216639","phase":"","title":"Feasibility Study of the Proposed Test-and-treat Screening Program in Younger Participants With H. Pylori Infection","status":"UNKNOWN","sponsor":"National Institute of Public Health, Slovenia","startDate":"2024-02-01","conditions":"Helicobacter Pylori Infection","enrollment":2000},{"nctId":"NCT03779074","phase":"PHASE3","title":"Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies","status":"COMPLETED","sponsor":"Kaohsiung Veterans General Hospital.","startDate":"2018-09-03","conditions":"Helicobacter Pylori Infection","enrollment":918},{"nctId":"NCT03779087","phase":"NA","title":"Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection","status":"COMPLETED","sponsor":"Ping-I (William) Hsu, M.D.","startDate":"2018-07-11","conditions":"Helicobacter Pylori Infection","enrollment":112},{"nctId":"NCT06065267","phase":"PHASE4","title":"Levofloxacin Concomitant Versus Levofloxacin Sequential","status":"NOT_YET_RECRUITING","sponsor":"Damascus Hospital","startDate":"2024-01-02","conditions":"Helicobacter Pylori Infection","enrollment":150},{"nctId":"NCT06050824","phase":"PHASE4","title":"A Comparative Study Between Concomitant Versus Load Therapy in Eradication of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Helwan University","startDate":"2022-07-21","conditions":"H. Pylori Infection","enrollment":200},{"nctId":"NCT05850117","phase":"NA","title":"Efficacies of Tetracycline-levofloxacin, Standard Bismuth, Amoxicillin-levofloxacin Quadruple Therapy for H.p","status":"UNKNOWN","sponsor":"Kaohsiung Medical University","startDate":"2020-02-10","conditions":"Helicobacter Pylori Eradication","enrollment":240},{"nctId":"NCT02800785","phase":"NA","title":"The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05","conditions":"Appendicitis","enrollment":1552},{"nctId":"NCT05669651","phase":"NA","title":"Explore the Efficacy and Safety of FMT With Different Bacterial Doses in the Treatment of Hepatic Encephalopathy","status":"UNKNOWN","sponsor":"Hainv Gao","startDate":"2022-12-01","conditions":"Hepatic Encephalopathy","enrollment":100},{"nctId":"NCT04660123","phase":"PHASE4","title":"A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2020-12-20","conditions":"Gastric Cancer, Helicobacter Pylori Infection, Bismuth","enrollment":959},{"nctId":"NCT03148366","phase":"PHASE3","title":"Comparison of the Levofloxacin Sequential Therapy and Quadruple Therapy in Second Line Treatment for HP","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Helicobacter","enrollment":560},{"nctId":"NCT05293977","phase":"NA","title":"Short-Term Use of Antibiotics and Adherence Level","status":"COMPLETED","sponsor":"Jordan University of Science and Technology","startDate":"2020-08-03","conditions":"Acute Infection","enrollment":589},{"nctId":"NCT05250050","phase":"PHASE4","title":"Susceptibility-Guided Therapy for Helicobacter Pylori Infection Treatment","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-03-25","conditions":"Helicobacter Pylori Infection","enrollment":388},{"nctId":"NCT05126121","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Xiuli Zuo","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT05133193","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT05129176","phase":"PHASE4","title":"Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-23","conditions":"Helicobacter Pylori Infection","enrollment":106},{"nctId":"NCT05061732","phase":"PHASE4","title":"Helicobacter Pylori Eradication and Follow-up","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-09-30","conditions":"Helicobacter Pylori Infection","enrollment":4447},{"nctId":"NCT05023577","phase":"PHASE4","title":"Antibiotic Combination for H. Pylori Eradication in Penicillin-allergic Patients","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08-26","conditions":"Helicobacter Pylori Infection","enrollment":504},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04107194","phase":"PHASE3","title":"Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.","status":"UNKNOWN","sponsor":"University of Bari","startDate":"2020-01-14","conditions":"Helicobacter Pylori Infection, Antibiotic Resistant Infection, Antibiotic Resistant Strain","enrollment":362},{"nctId":"NCT03236961","phase":"NA","title":"Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Turku University Hospital","startDate":"2017-04-03","conditions":"Acute Appendicitis","enrollment":552},{"nctId":"NCT03257423","phase":"NA","title":"Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2017-04-04","conditions":"Acute Appendicitis","enrollment":200},{"nctId":"NCT03234296","phase":"NA","title":"Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis","status":"ENROLLING_BY_INVITATION","sponsor":"Turku University Hospital","startDate":"2017-08-09","conditions":"Acute Appendicitis","enrollment":147},{"nctId":"NCT04432233","phase":"PHASE4","title":"Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-06-15","conditions":"Helicobacter Pylori Infection, Intravenous Drug Usage","enrollment":60},{"nctId":"NCT03658746","phase":"PHASE4","title":"Efficacies of Antimicrobial Susceptibility-Guided Versus Empirical Therapy for Rescue Treatment of Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shandong University","startDate":"2019-01-01","conditions":"Helicobacter Pylori Infection","enrollment":420},{"nctId":"NCT03565484","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the Rescue Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2019-01-01","conditions":"Helicobacter Pylori Infection","enrollment":400},{"nctId":"NCT04359966","phase":"NA","title":"Prospective Randomised Trial of First and Second Line Treatments of RCT of First and Second Line H Pylori Treatments in Slovenia","status":"UNKNOWN","sponsor":"Slovenian Society for Gastroenterology and Hepatology","startDate":"2020-05-10","conditions":"Helicobacter Pylori Infection, Eradication Treatments","enrollment":560},{"nctId":"NCT04353362","phase":"PHASE4","title":"Alternative Antibiotic Regimen in Periodontitis Treatment","status":"COMPLETED","sponsor":"Istanbul Medipol University Hospital","startDate":"2017-04-01","conditions":"Amoxicillin, Metronidazole, Ofloxacin","enrollment":74},{"nctId":"NCT03708848","phase":"PHASE4","title":"Tailored Therapy for Helicobacter Pylori Treatment in Patients With Penicillin Allergy","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-12-05","conditions":"Helicobacter Pylori Infection","enrollment":112},{"nctId":"NCT04039412","phase":"PHASE4","title":"Comparison Between Quadruple Regimens for Helicobacter Pylori Infection in Egypt","status":"COMPLETED","sponsor":"Ayman Magd Eldin Mohammad Sadek","startDate":"2018-06-01","conditions":"Helicobacter Pylori Infection","enrollment":330},{"nctId":"NCT01951768","phase":"PHASE4","title":"Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2013-09","conditions":"Diabetic Foot Ulcer","enrollment":88},{"nctId":"NCT04090021","phase":"PHASE4","title":"Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.","status":"UNKNOWN","sponsor":"Konstantopoulio-Patission General Hospital of Nea Ionia","startDate":"2019-09-01","conditions":"Helicobacter Pylori Infection","enrollment":304},{"nctId":"NCT04061447","phase":"NA","title":"Tailored Juice-guided Eradication Therapy","status":"COMPLETED","sponsor":"Kaohsiung Medical University","startDate":"2016-02-05","conditions":"Helicobacter Pylori Infection","enrollment":182},{"nctId":"NCT04031664","phase":"PHASE4","title":"A Clinical Study on Qianjin Capsule of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Damp-heat Stasis and Qi Deficiency Syndrome)","status":"UNKNOWN","sponsor":"China Academy of Chinese Medical Sciences","startDate":"2019-08-02","conditions":"Pelvic Inflammatory Diseases","enrollment":184},{"nctId":"NCT04035785","phase":"PHASE4","title":"A Clinical Study on Kangfu Anti-inflammatory Suppository of Gynaecology Combined With Antibiotics for Pelvic Inflammatory Diseases (Evidence of Dampness and Heat Accumulation)","status":"UNKNOWN","sponsor":"China Academy of Chinese Medical Sciences","startDate":"2019-07-28","conditions":"Pelvic Inflammatory Diseases","enrollment":240},{"nctId":"NCT02894268","phase":"PHASE4","title":"Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy","status":"UNKNOWN","sponsor":"Sir Run Run Shaw Hospital","startDate":"2016-02","conditions":"Helicobacter Pylori Infection","enrollment":300},{"nctId":"NCT02935010","phase":"PHASE4","title":"Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2017-02-05","conditions":"Helicobacter Pylori Infection","enrollment":382},{"nctId":"NCT03413020","phase":"PHASE4","title":"Tailored Therapy for Helicobacter Pylori Rescue Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-01-03","conditions":"Helicobacter Pylori Infection","enrollment":200},{"nctId":"NCT01022567","phase":"NA","title":"Appendicectomy Versus Antibiotics in the Treatment of Acute Uncomplicated Appendicitis","status":"UNKNOWN","sponsor":"Turku University Hospital","startDate":"2009-11","conditions":"Acute Appendicitis","enrollment":530},{"nctId":"NCT03571230","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2018-07-01","conditions":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","enrollment":400},{"nctId":"NCT03555526","phase":"PHASE4","title":"Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-12-15","conditions":"H Pylori Infection","enrollment":320},{"nctId":"NCT02576236","phase":"NA","title":"Therapeutic Trial Comparing Triple Therapy Guided by the PCR Detection of Clarithromycin Resistance vs Empiric Concomitant Quadruple Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05","conditions":"H Pylori Infection Eradication, Antibiotics Therapeutic Strategies, H Pylori Eradication","enrollment":2500},{"nctId":"NCT01725906","phase":"PHASE4","title":"Genotypic Resistance Guided Therapy in Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-11","conditions":"Self Efficacy","enrollment":450},{"nctId":"NCT03139253","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment","status":"UNKNOWN","sponsor":"Yanqing Li","startDate":"2017-05-30","conditions":"Antimicrobial Susceptibility Testing, Triple Therapy","enrollment":120},{"nctId":"NCT02988089","phase":"PHASE4","title":"Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2017-04-20","conditions":"Helicobacter Pylori Infection, Antimicrobial Susceptibility Testing","enrollment":480},{"nctId":"NCT02422706","phase":"PHASE3","title":"Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2015-01","conditions":"Helicobacter-associated Gastritis","enrollment":120},{"nctId":"NCT02596620","phase":"NA","title":"Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2013-10","conditions":"Helicobacter Pylori Infection","enrollment":164},{"nctId":"NCT02934048","phase":"PHASE4","title":"Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2016-10","conditions":"Therapeutic Duration, Helicobacter Pylori, Antimicrobial Susceptibility Test","enrollment":700},{"nctId":"NCT02466919","phase":"PHASE4","title":"Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients","status":"COMPLETED","sponsor":"Chung-Tai Wu","startDate":"2014-05","conditions":"Helicobacter Pylori Infection","enrollment":114},{"nctId":"NCT02741414","phase":"NA","title":"A Multi-center Study for Eradication of Refractory Helicobacter Pylori","status":"UNKNOWN","sponsor":"Taizhou Hospital","startDate":"2016-06","conditions":"Gastritis","enrollment":4428},{"nctId":"NCT02789865","phase":"PHASE2","title":"Clinical Trial Comparing ERAT vs Antibiotic Therapy vs Appendectomy for Treatment of Uncomplicated Acute Appendicitis","status":"UNKNOWN","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2016-05","conditions":"Acute Appendicitis","enrollment":240},{"nctId":"NCT02759029","phase":"NA","title":"Development of Treatment Algorithm for Eradication of Helicobacter Pylori Based on Antibiotic Susceptibility Test","status":"UNKNOWN","sponsor":"Gangnam Severance Hospital","startDate":"2016-03","conditions":"Helicobacter Pylori Infection","enrollment":123},{"nctId":"NCT02689583","phase":"NA","title":"A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2016-03","conditions":"Gastritis, Gastric Ulcer","enrollment":3000},{"nctId":"NCT01537055","phase":"PHASE4","title":"Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2012-02","conditions":"Eradication Rate for Helicobacter","enrollment":600},{"nctId":"NCT00683865","phase":"PHASE3","title":"Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.","status":"COMPLETED","sponsor":"Bayer","startDate":"2003-04","conditions":"Pelvic Inflammatory Disease","enrollment":749},{"nctId":"NCT00453349","phase":"PHASE3","title":"A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-01","conditions":"Pelvic Inflammatory Disease","enrollment":460},{"nctId":"NCT01742429","phase":"PHASE4","title":"Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2012-11","conditions":"Cure Rate of Helicobacter Pylori Infection","enrollment":200},{"nctId":"NCT01163435","phase":"PHASE4","title":"Efficacy of High Dose Dual Therapy, Sequential Therapy and Triple Therapy in H. Pylori Eradication","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2010-08","conditions":"Helicobacter Infection","enrollment":618},{"nctId":"NCT01799356","phase":"PHASE4","title":"Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials","status":"COMPLETED","sponsor":"Istanbul Bakirkoy Maternity and Children Diseases Hospital","startDate":"2010-06","conditions":"Pelvic Inflammatory Disease","enrollment":1303},{"nctId":"NCT01032655","phase":"PHASE4","title":"The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-04","conditions":"Helicobacter Pylori Infection","enrollment":134},{"nctId":"NCT00236912","phase":"PHASE4","title":"A Study Comparing Safety and Efficacy of Levofloxacin and Metronidazole Versus Piperacillin/Tazobactam in Treating Complicated Appendicitis","status":"TERMINATED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-07","conditions":"Appendicitis","enrollment":139},{"nctId":"NCT00885417","phase":"PHASE4","title":"The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2009-04","conditions":"H. Pylori Infection","enrollment":142},{"nctId":"NCT01241110","phase":"PHASE4","title":"To Compare Ofloxacin With Azitromycin for Pelvic Inflammatory Disease (PID) Treatment","status":"COMPLETED","sponsor":"Guilan University of Medical Sciences","startDate":"2010-01","conditions":"Pelvic Inflammatory Disease","enrollment":100},{"nctId":"NCT00752947","phase":"PHASE4","title":"Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors","status":"UNKNOWN","sponsor":"Beijing Hospital","startDate":"2008-09","conditions":"Community-Acquired Pneumonia","enrollment":186}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"levofloxacin; metronidazole","genericName":"levofloxacin; metronidazole","companyName":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","companyId":"johnson-johnson-pharmaceutical-research-development-l-l-c","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses levofloxacin (a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV) and metronidazole (a nitroimidazole that damages bacterial DNA) to provide broad-spectrum anaerobic and aerobic bacterial coverage. Used for Mixed aerobic and anaerobic bacterial infections, Intra-abdominal infections, Pelvic inflammatory disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}